newsfilter
← Latest News
GlobeNewswire·

Incannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42X

NEW YORK and MELBOURNE, Australia, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company developing